Asamedic is a Norwegian pharmaceutical company established in 2015 with the purpose of developing a drug against acute myocardial infarction.
The result became Coxor®, developed between 2015 – 2022, and launched with success in Norway in 2023 following approval in a European DCP.
Coxor® is patented in most parts of the world, and Asamedic is signing licensing agreements with LifeScience companies for global expansion.
Asamedic was established by Per Erik Stribolt-Halvorsen, Geir Ivar Westen and Tore Ritter Westen. Stribolt-Halvorsen was personally motivated after losing both his father and brother to heart attacks and commenced research to find a way to reduce mortality from heart attacks
The company commenced full operations. It received positive feedback from patent authorities on feasibility study and delivered a patent application resulting in patent pending status word-wide. Series 1 Funding Round of MNOK 3.9
First prototype produced. Asamedic received funds from Innovation Norway and was approved SkatteFunn-status by The Research Council of Norway. The firm became a member of the Norwegian Medical Association. Patent pending on two new applications
Series 2 Funding Round, MNOK 15. Very positive dissolution test after R&D on solvent. Asamedic elects new board of directors and establishes Advisory Board
External marketing analysis conducted, with very positive results showing high market acceptance and willingness to purchase. 6,000 vials set in stability program
Application for marketing authorization. Patent application moves from patent pending status to patent granted in Australia. Generation II container development started with Inventas and NTNU. Marketing Application submitted for Coxor in December 2019
Enter partnership with ELC and Convex to conduct clinical trial on Coxor with new methodology to reveal important clinical data on ASA behavior. 18 months stability data shows positive outcome. Initiates dialogue with potential industry partners
Reaches end of DCP procedure January 19th with positive outcome. Completes national phase for Norway and Denmark and receives local Marketing Authorizations. In addition, OTC status is achieved.
Positive article from clinical trial published. Asamedic out-licenses rights of Coxor® in the Nordics to Evolan Pharma AB. Coxor will be launched in the near future, with Norway being the first market.
Coxor launched in Norway in February 2023 with great success. Feedback for authorities, media and KOLs very positive.
Asamedic initiates own outreach to potential licensing partners. Attends CPHI Milano in October with own booth, resulting in >100 companies interested in licensing Coxor for various parts of the world.
